Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single‐center experience. Issue 4 (26th January 2021)

• Record Type: Journal Article
• Authors: Lombardi, Pietro Maria; Mazzola, Michele; Achilli, Pietro; Aquilano, Maria Costanza; De Martini, Paolo; Curaba, Annabella; Gualtierotti, Monica; Bertoglio, Camillo L.; Magistro, Carmelo; Ferrari, Giovanni
• Is Part Of: Journal of surgical oncology. Volume 123:Issue 4(2021)
• Page Start: 923
• Page End: 931
• Publication Date: 2021-01-26
• Subjects: gastric cancer -- neoadjuvant chemotherapy -- survival -- tumor regression grade -- ypTNM; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26391
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background and Objective: Perioperative chemotherapy (PC) with radical surgery represents the gold standard of treatment for resectable advanced gastric cancer (GC). The prognostic value of pathological tumor regression grade (TRG) induced by neoadjuvant chemotherapy (NACT) is not clearly established. This study aimed to investigate the correlation between TRG and survival in GC. Methods: Patients affected by advanced GC undergoing PC and radical surgery were considered. TRG was assessed for each patient according to Becker's grading system. The correlation between TRG and survival was investigated. Results: One‐hundred patients were selected; 25 showed a good response (GR) (TRG 1a/1b), while 75 had a poor response (PR) (TRG 2/3) to NACT. GR patients showed better disease‐free survival (DFS) (52 vs. 19 months, p < .001) and disease‐specific survival (DSS) (57 vs. 25 months, p < .0001) when compared to PR patients. On univariate analysis, TRG, lymph node ratio (LNR), tumor size, grading, and post‐neoadjuvant therapy TNM stage were significantly correlated with survival. On multivariate analysis, TRG, LNR and tumor size were independent prognostic factors for DFS and DSS. Conclusions: TRG, LNR, and tumor size are independent prognostic factors for DFS and DSS in patients with advanced GC undergoing NACT.